The present disclosure relates to a method for producing natural killer (NK) cells. More specifically, the present disclosure relates to a method for producing NK cells, characterized in that peripheral blood mononuclear cells from which CD3-positive cells are removed are proliferated together with feeder cells, and the peripheral blood mononuclear cells are re-stimulated with feeder cells at the time of reaching a specific accumulated population doubling level. The present disclosure also relates to a method for producing NK cells, characterized in that NK cells are cultured under appropriate culture conditions by using a bioreactor. The production method according to the present disclosure has an advantage that NK cells having a high cell-killing ability and cell survival rate can be produced with high purity and at high efficiency in a short period of time by a clinically friendly method as compared with existing methods, thereby increasing the productivity of an NK cell therapy agent.

Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided herein are tumor organoids developed using such organoid culture systems, methods for assessing the clonal diversity of the tumor organoids, and methods for using such tumor organoids, for example, for tumor modelling and drug development applications. In particular embodiments, the tumor organoid culture media provided herein is substantially free of R-spondins (e.g., R-spondin1).

3D cell cultures contain hepatic cells and are infected by a pathogen. Such cell cultures are prepared by, for example, inoculating a single-cell suspension containing hepatic cells expanded in a 2D culture in an agitation-based culture system. Next, the resulting cell culture is agitated at a given agitation rate. Then, the resulting 3D cell culture containing cell aggregates is incubated with a pathogen.

The present invention provides a method of inducing cell death by hyperactivation of motility networks.

Provided is a method of culturing mesenchymal stem cells as a cell construct while maintaining undifferentiation thereof, the method including subjecting mesenchymal stem cells to shaking culture.

The present invention relates to providing artificial tendon or ligament tissue having sufficient strength. More specifically, artificial tendon or ligament tissue having sufficient strength is provided by embedding collagen-secreting cells in a gel having strength capable of resisting a tensile load and by culturing the cells while applying a tensile load to the gel to produce artificial tendon or ligament tissue. Cells that steadily express the Mkx gene can be used as the collagen-secreting cells. A fibrin gel containing aprotinin can be used as the gel.

Disclosed herein are methods of enhancing development of a three-dimensional in vitro model of an intestinal tissue (HIO), which may be derived from a precursor cell. The precursor cell may be, for example, an embryonic stem cell, an induced pluripotent stem cell (iPSC), or the like. The in vitro HIO model may be characterized in that the HIO has a lumen, in which a lengthening device may be inserted to promote development of the HIO. Compositions derived from the disclosed methods are also described.

Methods for isolating a population of cells from tissue are disclosed herein. In particular, the present disclosure provides methods for isolating cytotrophoblasts from placental tissue. The methods include isolating a population of cells with the use of a laboratory apparatus that is coated with a lubricant, such as petroleum jelly. The methods described herein achieve consistent in vitro isolation of purified cells.

The invention relates to a compacted tissue of human cardiac cells expressing cardiac troponin C, which is contractile and has a low spontaneous contraction frequency. The invention also relates to the use of the tissue, in particular in the treatment of a cardiac pathology, particularly ischaemic heart disease.

The present invention relates to a novel bioreactor system for cell cultivation. More specifically, the invention relates to a compact bioreactor system which has several integrated functions and enables small scale static culture as well as scale-up rocking culture in the same bioreactor. The bioreactor system comprises tray for positioning of a cell culture bag having adjustable volume, a lid covering the cell culture bag and provided with heating function, an integrated perfusion unit, an integrated cell loading unit, and an integrated unit for automatic cell culture sampling, wherein the bioreactor system is controlled by a single control unit. The invention also relates to a method of cell culture using the bioreactor system for culture of therapeutic cells.